Behçet’s Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Behçet’s disease (BD) is an uncommon yet profoundly incapacitating vasculitis, primarily characterized by mucocutaneous manifestations, including orogenital ulcers and skin lesions. Notably, BD can affect various organ systems, such as the musculoskeletal, ocular, nervous, gastrointestinal, vascular, urogenital, and cardio-pulmonary systems, resulting in considerable morbidity and mortality. The diagnosis of BD is often delayed due to the variability and intermittency of symptoms, the necessity to exclude mimicking conditions, the absence of a specific blood test or disease marker, and a general lack of awareness about the disorder. The etiology of BD is unknown, with genetic predisposition potentially permitting specific infectious agents, particularly Streptococcus sanguis, or environmental factors to trigger inflammatory attacks resembling auto-inflammatory disorders through cross-reactions with oral mucosa antigens. The HLAB5101 antigen is implicated in 50-60% of BD cases, while NF-kB activation and abnormal cytokine levels (e.g., IL-6, TNF-a, IL-8, IL-12, IL-17, and IL-21) play a role in the pathogenesis of BD. A familial, autosomal dominant form of BD, associated with A20 haploinsufficiency, is linked to mutations in TNFAIP3(6q23.3). Although BD most commonly emerges in adults (mean age 30 years), pediatric cases have been reported, presenting with relapsing episodes of round oral aphthae, genital aphthae, and cutaneous features such as pseudo-folliculitis and erythema nodosum. Ocular disorders, including posterior uveitis and retinal vasculitis, occur in over 50% of BD patients. The differential diagnosis depends on the specific manifestations and conditions such as herpes ulcerations, spondylo-arthropathies, infectious uveitis, relapsing polychondritis, sarcoidosis, antiphospholipid syndrome, Takayasu arteritis, Crohn’s disease, contagious meningoencephalitis, or multiple sclerosis may be considered. The primary treatment for BD involves anti-inflammatory steroids; however, corticosteroid dependence and relapses may ensue upon discontinuation. Concurrent administration of immunosuppressive drugs (e.g., azathioprine, cyclophosphamide, methotrexate, or mycophenolate mofetil) is also prescribed, although their therapeutic effects are delayed. Recently, Apremilast has gained approval for refractory oral ulceration in BD. Without treatment, BD prognosis is severe, posing risks such as ocular complications leading to potential blindness, lethal arterial rupture, large vessel thrombosis, and neurological symptoms that may result in encephalopathy or cerebral hypertension, leading to a loss of autonomy. Intensive care, close multidisciplinary follow-up, and tailored immunosuppressive treatment have demonstrated efficacy in reducing morbidity and mortality.
• In the United States, the prevalence of Behçet’s disease is reported to be 5.2 per 100,000 individuals.

Thelansis’s “Behçet’s Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Behçet’s Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Behçet’s Disease across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Behçet’s Disease Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Behçet’s Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033